For the quarter ending 2025-09-30, STRO had $1,902K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 90,837 | - |
| Personnel-related expenses | 66,680 | - |
| Outside services | 55,077 | - |
| Preclinical research and clinical development expenses | 5,623 | - |
| Laboratory supplies | 9,201 | - |
| Facility and maintenance expenses | 11,129 | - |
| Equipment and office-related expenses | 13,768 | - |
| Travel-related expenses | 654 | - |
| Restructuring and related costs | 49,023 | - |
| Operating expenses | 211,155 | - |
| Loss from operations | -120,318 | - |
| Non-cash interest expense related to the sale of future royalties | 28,661 | - |
| Interest income | 7,717 | - |
| Interest and other income (expense), net | -3,073 | - |
| Non-operating loss | -24,017 | - |
| Loss before provision for income taxes | -144,335 | - |
| Income tax expense | -11 | - |
| Net loss | -56,857 | -87,467 |
| Depreciation and amortization | 1,900 | 3,800 |
| Accretion of discount on marketable securities | 755 | 2,149 |
| Stock-based compensation | 1,552 | 10,801 |
| Non-cash lease expenses | 1,495 | 2,841 |
| Realized gain on sale of equity securities | 0 | 0 |
| Non-cash interest expense on deferred royalty obligation | 9,670 | 18,991 |
| Other | -157 | -303 |
| Accounts receivable | -4,077 | -617 |
| Prepaid expenses and other assets | -7,953 | -6,421 |
| Accounts payable | 2,683 | -5,726 |
| Accrued compensation | 1,484 | -1,141 |
| Accrued expenses and other liabilities | -3,481 | 7,112 |
| Deferred revenue | -6,135 | -63,449 |
| Change in operating lease liability | -1,932 | -3,561 |
| Net cash used in operating activities | -38,189 | -112,607 |
| Purchases of marketable securities | 89,938 | 170,973 |
| Maturities of marketable securities | 115,516 | 135,750 |
| Sales of marketable securities | 14,662 | 22,805 |
| Proceed from sale of equity securities | 0 | - |
| Purchases of equipment and leasehold improvements | 251 | 1,260 |
| Net cash provided by investing activities | 39,989 | -13,678 |
| Proceeds from sales of common stock, net of issuance costs | 0 | 0 |
| Proceeds from sales of common stock to ipsen biopharmaceuticals, inc. (usa) | 0 | 0 |
| Payment of debt | 0 | 0 |
| Proceeds from exercise of common stock options | 1 | 0 |
| Taxes paid related to net shares settlement of restricted stock units | 25 | 240 |
| Proceeds from employee stock purchase plan | 126 | 246 |
| Net cash provided by financing activities | 102 | 6 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 1,902 | -126,279 |
| Cash and cash equivalents at beginning of period | 191,162 | - |
| Cash and cash equivalents at end of period | 66,785 | - |
SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC. (STRO)